Barclays Maintains Overweight on Celldex Therapeutics, Raises Price Target to $48
Benzinga Newsdesk 6 months ago
NewsPrice TargetAnalyst Ratings
Barclays analyst Etzer Darout maintains Celldex Therapeutics (NASDAQ:CLDX) with a Overweight and raises the price target from $45 to $48.
Barclays analyst Etzer Darout maintains Celldex Therapeutics (NASDAQ:CLDX) with a Overweight and raises the price target from $45 to $48.